Kornimate/medical-research-clean huggingface dataset:
topical remetinostat in treating patient with cutaneous basal cell cancer

Conditions: Skin Basal Cell Carcinoma

Summary: this phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. remetinostat may slow the growth of basal cell cancer cells.

primary objectives: i. overall response rate of basal cell carcinoma (bcc) in subjects at 6 weeks. secondary objectives: i. suppression of gli1 (glioma-associated oncogene) expression in treated bccs as compared with baseline. ii. safety assessment of remetinostat after 6 weeks of topical treatment. outline: tumors receive remetinostat topically three times per day (tid) for 6 weeks in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed for at least 4 weeks.

Eligibility criteria:
inclusion criteria: * must have at least one bcc lesion \> 1 cm (bcc \> 5 mm) in non-cosmetically sensitive site(s) * must be willing to apply the topical remetinostat 3 times daily for 6 weeks * for women of child bearing potential, a negative urine pregnancy test * women of child bearing potential are expected to use an effective method of birth control while participating in the study and for 1 month after applying the last dose * for male subjects with female partners of childbearing potential, agreement to use adequate contraception while participating in the study and for 1 month after applying the last dose * has signed and dated the current institutional review board (irb) approved informed consent document exclusion criteria: * taking any medication known to interact with histone deacetylase (hdac) inhibitors, such as valproate or anticoagulants * taking any medication known to affect hedgehog (hh) signaling pathway such as itraconazole * within the past 6 months, has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study; specifically, these include the topical use to the study tumors of: * glucocorticoids * retinoids either systemically or topically (eg, etretinate, isotretinoin, tazarotene, tretinoin, adapalene) * alpha hydroxy acids (eg, glycolic acid, lactic acid) to \> 5% of the skin * 5 fluorouracil or imiquimod and/or * itraconazole * has received treatment with systemic chemotherapy or agents known to be inhibitors of hh signaling, within 60 days to starting study medication * currently receiving systemic medications that could affect bcc tumors (eg, oral retinoids) or might interact with remetinostat * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recurrent seizure history or psychiatric illness/social situations that would limit compliance with study requirements * moderate to severe immunosuppression due to disease or medication * known or previous hypersensitivity to histone deacetylase inhibitor (hdaci) * history of congestive heart failure; cardiac arrhythmias; or other findings of ventricular dysfunction * history of current evidence of malabsorption or liver disease * pregnancy or breast feeding
post-extubation boussignac cpap system in adults with moderate to severe obstructive sleep apnea

Conditions: Obstructive Sleep Apnea (OSA)

Summary: the purpose of this study is to assess the efficacy of the boussignac positive airway pressure system (a mask) applied immediately following post-operative extubation in improving lung function in patients with obstructive sleep apnea (osa). assessments will be done before surgery and then at 1, 2 and 24 hours following extubation and will be compared to standard care for perioperative airway support. the study aims to give a broader and more inclusive picture (than the current literature) in terms of whether the boussignac cpap system should be considered for utilization by anesthesiologists caring for surgical patients with osa.


Eligibility criteria:
inclusion criteria: -\> 18 years of age * asa ii-iv * previous diagnosis of moderate to severe obstructive sleep apnea * diagnosed via polysomnography * bmi \< 40 * scheduled for an abdominal or peripheral surgical procedure requiring endotracheal intubation and admission to hospital exclusion criteria: * bmi \> 40 * age \<18 years * inability to provide signed informed consent * intra-thoracic * head or neck surgery * contraindication for immediate post-extubation application of cpap * not expected to be eligible for timely extubation following the surgical procedure

Keywords: obstructive sleep apnea, cpap, boussignac
myostrain cmr for the detection of cardiotoxicity

Conditions: Cardiotoxicity; Heart Failure; Chemotherapeutic Toxicity

Summary: the prefect pilot study evaluates the use of the ec approved myostrain senc cmr imaging system to detect cardiotoxicity from drugs used to treat cancer (e.g. breast cancer and lymphomas).

the study is a prospective, observational, single center, observational clinical study that will enroll up to 50 patients undergoing chemotherapy and/or targeted therapy with or without concomitant radiotherapy for the treatment of breast cancer or lymphoma. enrolled subjects will be evaluated with the myostrain senc cmr imaging system that measures myocardial strain during standard cardiac magnetic resonance imaging at baseline through 6 month follow-up. the myostrain senc cmr imaging system has been approved with an ec certificate according to directive 93/42/eec on medical devices, annex ii excluding section 4 (ce 657862) in respect of: design, development and manufacture of software for the quantification of cardiac mri images. myostrain measures the contraction of heart muscle in one heartbeat per image plane. with 6 image planes (3 short axis \& 3 long axis), a complete measure of the health of the myocardium, both regionally and globally, can be obtained within a minute without requiring contrast injection or a breath-hold. heart health will be monitored throughout cancer therapy to quantify the toxic effects of chemotherapy with or without a reduction in traditional measures such as ejection fraction, and the ability to reverse observed cardiotoxicity with standard heart failure therapy. the goal of the study is to determine the ability to detect subclinical cardiotoxicity before extensive damage causes the reduction in traditional measures, which are currently used to categorize heart failure and serve as the basis of treatment guidelines.

Eligibility criteria:
inclusion criteria: * undergoing chemotherapy for cancer treatment * provided written informed consent exclusion criteria: * contraindication to magnetic resonance imaging * pregnancy

Keywords: strain
role of hematological parameters in the stratification of covid-19 disease severity

Conditions: Covid19

Summary: the hemostatic abnormalities in covid-19 are related with disease progression, severity and mortality. the objective of our study is to evaluate the role of hematological parameters in determination of covid-19 disease severity.

objective: covid-19 virus involves respiratory as well as other body systems including cardiovascular, gastrointestinal, neurological, immunological and hematopoietic system. patient of covid-19 pneumonia presents with wide range of hemostatic abnormalities. these hemostatic abnormalities in covid-19 are related with disease progression, severity and mortality. the objective of our study is to evaluate the role of hematological parameters in determination of covid-19 disease severity. material and method: this was a retrospective study, conducted in department of pathology and department of medicine, fmh college of medicine and dentistry from may 2020 to july 2020. total of 101, confirmed cases of covid-19 disease, both genders between 17 to 75-year age were included. hematological parameters were compared in mild, moderate, severe and critical disease group. continuous variables were analyzed by using non parametric, kruskal wallis test while categorical variables were analyzed by chi-square test.

Eligibility criteria:
inclusion criteria: * diagnosed cases of covid-19 disease * both genders * 17 to 75 year age exclusion criteria: * known case of chronic liver disease * known hematological diseases were excluded

Keywords: covid-19 disease neutrophil to lymphocyte ratio hematological manifestations
artificial intelligence to predict surgical outcomes and assess pain neuromodulation in trigeminal neuralgia subjects

Conditions: Trigeminal Neuralgia; Trigeminal Nerve Diseases; Virtual Reality; Artificial Intelligence; Radiosurgery; Magnetic Resonance Imaging

Summary: trigeminal neuralgia (tn) is the most common cause of facial pain. medical treatment is the first therapeutic choice whereas surgery, including gamma knife radiosurgery (gkrs), is indicated in case of pharmacological therapy failure. however, about 20% of subjects lack adequate pain relief after surgery. virtual reality (vr) technology has been explored as a novel tool for reducing pain perception and might be the breakthrough in treatment-resistant cases. the investigators will conduct a prospective randomized comparative study to detect the effectiveness of gkrs aided by vr-training vs gkrs alone in tn patients. in addition, using mri and artificial intelligence (ai), the investigators will identify pre-treatment abnormalities of central nervous system circuits associated with pain to predict response to treatment. the investigators expect that brain-based biomarkers, with clinical features, will provide key information in the personalization of treatment options and bring a huge impact in the management and understanding of pain in tn.


Eligibility criteria:
inclusion criteria: * diagnosis of tn according to the international classification of headache disorders, third edition (ichd-3) criteria; * age \>18 years; * indication to undergo radiosurgical treatment; * willingness and ability to comply with scheduled visits and other trial procedures. exclusion criteria: * any person unable to lie still within the environment of the mri scanner for the required period to perform the study and those where mri scanning is contraindicated; * metal implants, pacemaker, etc.; * pregnancy or breastfeeding; * any significant psychiatric disease; * use of illicit drugs; * brain pathology shown by brain mri and/or neurophysiological examination; * any person unable to understand and follow the instructions of the investigators; * any other condition according to the investigator would make the subject unsuitable for the study.
study of medi-507 in with steroid-resistant acute graft-versus-host disease

Conditions: Cancer; Graft-Versus-Host Disease

Summary: a clinical trial to assess safety and two regimens of (medi-507) a drug given to stem cell and bone marrow recipients who have a mid-grade acute graft-versus-host disease.

to assess the safety of two regimens of medi-507 administered to stem cell and bone marrow allograft recipients who have at least grade ii acute gvhd and who have not achieved a satisfactory response to at least three days of corticosteroid therapy (2 mg/kg/day of methylprednisolone or its equivalent).

Eligibility criteria:
inclusion criteria: * allogeneic bone marrow or hematopoietic stem cell graft recipients * acute gvhd of at least grade ii severity * failure of gvhd to improve on at least 2 mg/kg/day of methylprednisolone or prednisone for at least three days or recurrence of acute gvhd as corticosteroids are tapered from initial treatment of the initial episode of gvhd * evidence of engraftment (anc over 1000 cells/mm3) * histologic evidence of gvhd from biopsy performed during the current episode * received gvhd prophylaxis of methotrexate, tacrolimus or cyclosporine * age at least 18 years * body weight under 130 kg * both males and females are eligible but females of childbearing potential will use an accepted method of avoiding pregnancy for at least 60 days after the end of treatment (which includes oral or implanted contraceptives, iud, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or a sterile sexual partner) exclusion criteria: * previous receipt of medi-507 * clinical or histologic manifestation of chronic gvhd * previous treatment with any anti-t-cell antibodies such as okt®3 or daclizumab (zenapax®) * receipt of antithymocyte globulin (atgam® or other atg) since the day of transplant * more than one allogeneic bone marrow or hematopoietic stem cell allograft * moribund and unlikely (in the opinion of the investigator) to survive 15 days * use of other investigational agents within 30 days (this does not include the use of licensed agents for indications not listed in the package insert) * any of the following clinical settings or diagnoses: ø documented or presumed significant active infection ø pregnancy or nursing mother ø evidence of infection with hiv-1, hepatitis b or c virus ø hemodialysis or chronic peritoneal dialysis ø use of a ventilator * histologically confirmed veno-occlusive disease of the liver * ascites on physical examination (this does not include small amounts of ascitic fluid detected only on ultrasound)
use of google translate to enhance patient pain and nausea assessment and satisfaction after general anesthesia

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this study investigates the use of google translate "conversation mode" translation service to improve communication about pain and nausea with spanish-speaking patients who are recovering after surgery. the google translate "conversation mode" translation application is designed to provide translation from one language to another and used to allow the nurse or study doctor to communicate with patients in spanish by asking pre-prepared questions through an electronic device such as an ipad or iphone. google translate "conversation mode" may facilitate assessment of pain and nausea after surgery in spanish speaking patients.

primary objective: i. to determine the feasibility of google translate "conversation mode" use to assess postoperative surgical pain presence, location and intensity, and nausea presence and intensity in spanish speaking patients in the post-anesthesia care unit (pacu). secondary objectives: i. to evaluate the length of stay in pacu. ii. to assess patient satisfaction with regards to pain/nausea experienced in pacu. iii. to determine nursing satisfaction with regards to the use of google translate "conversation mode". outline: patients use google translate "conversation mode" translation application before and after surgery. patients also complete survey over 10 minutes.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent * patients between 18-80 years of age whose primary language is spanish and will require translation services as part of standard care * american society of anesthesiologists physical status (asa) 1-3 * are scheduled surgery under general anesthesia * ability to understand and complete all study questionnaires exclusion criteria: * emergency surgery * asa \>= 4 * patients who do not require official translation services for consent purposes * patients who have chronic pain and/or are taking opioids chronically (daily intake for more than a month before surgery) * patients who undergo craniotomy * patients with a hearing impairment that prevents the ability to hear the recorded statements; and/or a cognitive impairment that would prevent them from completing post-op assessments
comparison of exsufflation versus drainage in primary spontaneous pneumothorax

Conditions: Pneumothorax

Summary: management of primary spontaneous pneumothorax (psp) remains unclear. primary therapeutic goals for psp include removal of air from the pleural space an prevention of recurrences. the absence of generally accepted and methodologically sound recommendations may account for the extensive variation in practice for air evacuation techniques. air evacuation may be achieved by simple aspiration (exsufflation) or conventional chest tube drainage. chest tube thoracotomy remains the most popular technique.aspiration is a more simple technique, that allows possibility of ambulatory management. the purpose of the present study is to compare simple aspiration performed with a specific thoracentesis device, versus conventional chest tube drainage. comparison will be performed on immediate efficacity of resolution of the pneumothorax.the hypothesis is that simple aspiration performed with a specific device is not inferior to chest tube drainage for management of a first episode of large size primary spontaneous pneumothorax. a second goal is to measure the efficacy at one week, and the recidive at one year. the trial is randomized, controlled and will include 200 patients for each group. the patients will be enrolled in 29 hospitals in france. emergency department, thoracic surgery and pulmonary departments of each hospital were primarily contacted for agreement to participate to the study.


Eligibility criteria:
inclusion criteria: * patients aged more than 18 years and less than 50 years * first episode of pneumothorax * primary pneumothorax (absence of known pulmonary disease) * large size of pneumothorax : presence of a visible rim of air between the lund margin and the chest wall, from the apex to pulmonary base exclusion criteria: * impossibility to obtain patient consent for psychiatric disease * patients under justice control * âgé less than 18 years, or more than 50 years * impossibility of medical follow de for geographic, social or psychic reasons * pregnant women * pneumothorax with acute respiratory insufficiency or bad tolerated * recidive of pneumothorax * traumatic pneumothorax * pneumothorax with pleural effusion * bilatéral pneumothorax * pneumothorax with pulmonary disease

Keywords: spontaneous primary first episode
accuracy of fnac in diagnosis of thyroid nodules

Conditions: Thyroid Nodule

Summary: detection of degree of accuracy of fnac in diagnosis of thyroid nodules

accuracy in diagnosis in any case is required, and this is beneficial to the patient and the physician, and with the development that currently exists and the trend to use less invasive techniques, accuracy of fnac should be studied well.1.thyroid nodules are common and the principal method of diagnosis is fine-needle aspiration cytology (fnac).2. can investigators depend on fnac alone in diagnosis of thyroid nodule in the future?!3. in this study, investigators will compare the results of (fnac) versus (biopsy) in diagnosis of thyroid nodule in auh , to detect the degree of accuracy of fnac.4. fnac is a simple, safe, cost-effective and accurate diagnostic tool for the initial screening of patients with thyroid nodules.5. background routine application of fine needle aspiration cytology (fnac) has decreased unnecessary referral of thyroid nodules for surgical treatment and has also increased the cancer rates found in surgery materials. success of thyroid fnac depends on skilled aspiration, skilled cytological interpretation and rational analysis of cytological and clinical data. the aim of this study was to determine the diagnostic accuracy rates of thyroid fnac results obtained in our hospital.6. the fnac is a sensitive, specific, and accurate initial diagnostic test for the preoperative evaluation of patients with thyroid swellings in our setting as well. the correlation of cytological and histopathological diagnoses is an important quality assurance method, as it allows cytopathologists to calculate their false-positive and false negative results.7

Eligibility criteria:
inclusion criteria: 1. thyroid disease 2. multinodular 3. single nodule 4. tirad 3 or more by us 5. thyroid disease underwent fnac then surgery 6. all age groups 7. patient fit for surgery exclusion criteria: 1. patients with comorbidities. 2. patients unfit for surgery 3. patients who refused surgery. 4. patient with no diagnostic fnac.
forces and translation distance during an inferior glide of the shoulder

Conditions: Asymptomatic Condition

Summary: this study evaluates the force and translation distance in the gh joint during a manual inferior glide of the humerus.

there has been limited research on how the variance of force affects mt outcomes and what the best practices of mt should be. no specific force threshold necessary to achieve a predetermined translational distance within the joint has been quantified within the literature. the purpose of this study was to quantify the amount of force necessary to perform an inferior glide to the glenohumeral joint and reach to end-range. a secondary aim was to determine the impact of co-variables, such as gender, height, weight, and age, on the amount of force required to translate the humeral head within the glenohumeral joint. musculoskeletal ultrasound imaging using the ge logiqe was used to measure the translation of the humeral head. the manipulation force was measured using the novel pliance glove device and software.

Eligibility criteria:
inclusion criteria: * healthy volunteers * able to read the english language fluently exclusion criteria: * a history of injury of the right shoulder * right shoulder surgery * presence of shoulder pain * comorbidities affecting natural rom within the dominant shoulder

Keywords: manipulation force glenohumeral joint musculoskeletal ultrasound imaging